INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 346 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 1.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,209,546 | -23.3% | 1,493,028 | -1.1% | 0.00% | -20.0% |
| Q2 2023 | $61,574,262 | -31.5% | 1,509,913 | -37.4% | 0.01% | +25.0% |
| Q1 2023 | $89,869,690 | +6.4% | 2,411,314 | -0.4% | 0.00% | -50.0% |
| Q4 2022 | $84,501,909 | -42.5% | 2,421,952 | -7.8% | 0.01% | -46.7% |
| Q3 2022 | $146,992,000 | -14.1% | 2,626,753 | -20.5% | 0.02% | -11.8% |
| Q2 2022 | $171,089,000 | -15.8% | 3,305,406 | +18.3% | 0.02% | +6.2% |
| Q1 2022 | $203,108,000 | -55.7% | 2,794,925 | -27.9% | 0.02% | -52.9% |
| Q4 2021 | $458,509,000 | +7.5% | 3,877,773 | +21.9% | 0.03% | 0.0% |
| Q3 2021 | $426,645,000 | -3.4% | 3,180,368 | +16.5% | 0.03% | -2.9% |
| Q2 2021 | $441,820,000 | +378.3% | 2,728,802 | +137.1% | 0.04% | +337.5% |
| Q1 2021 | $92,372,000 | +32.4% | 1,150,989 | -10.2% | 0.01% | +33.3% |
| Q4 2020 | $69,764,000 | +154.5% | 1,282,426 | -7.0% | 0.01% | +100.0% |
| Q3 2020 | $27,414,000 | -18.9% | 1,378,964 | -14.3% | 0.00% | -25.0% |
| Q2 2020 | $33,814,000 | +232.4% | 1,608,631 | +93.4% | 0.00% | +300.0% |
| Q1 2020 | $10,172,000 | -16.9% | 831,744 | -0.3% | 0.00% | 0.0% |
| Q4 2019 | $12,234,000 | +1147.1% | 833,927 | +1034.7% | 0.00% | – |
| Q3 2019 | $981,000 | -97.1% | 73,492 | -96.5% | 0.00% | -100.0% |
| Q2 2019 | $34,388,000 | -10.9% | 2,100,647 | -7.0% | 0.00% | -20.0% |
| Q1 2019 | $38,589,000 | +17.1% | 2,259,303 | -6.4% | 0.01% | 0.0% |
| Q4 2018 | $32,964,000 | -53.2% | 2,414,932 | -1.9% | 0.01% | -37.5% |
| Q3 2018 | $70,424,000 | +1.8% | 2,460,646 | -2.7% | 0.01% | 0.0% |
| Q2 2018 | $69,187,000 | -12.5% | 2,528,755 | -32.6% | 0.01% | -11.1% |
| Q1 2018 | $79,090,000 | -4.0% | 3,750,096 | -12.5% | 0.01% | -10.0% |
| Q4 2017 | $82,388,000 | +3.2% | 4,286,578 | +33.5% | 0.01% | 0.0% |
| Q3 2017 | $79,800,000 | +54.6% | 3,211,264 | -0.5% | 0.01% | +66.7% |
| Q2 2017 | $51,630,000 | -8.4% | 3,226,832 | -19.3% | 0.01% | -14.3% |
| Q1 2017 | $56,373,000 | -9.8% | 4,000,935 | -16.0% | 0.01% | -12.5% |
| Q4 2016 | $62,475,000 | -30.3% | 4,765,481 | -9.5% | 0.01% | -33.3% |
| Q3 2016 | $89,607,000 | -20.1% | 5,264,807 | +0.2% | 0.01% | -20.0% |
| Q2 2016 | $112,182,000 | – | 5,254,407 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,216,340 | $62,958,000 | 7.04% |
| Discovery Value Fund | 584,483 | $30,253,000 | 6.33% |
| MPM BioImpact LLC | 299,409 | $15,497,000 | 4.30% |
| ARK Investment Management | 9,514,580 | $439,003,000 | 2.60% |
| Elmwood Wealth Management, Inc. | 67,899 | $3,514,000 | 2.00% |
| Nikko Asset Management Americas, Inc. | 2,781,136 | $141,143,000 | 1.74% |
| Avidity Partners Management LP | 1,125,194 | $58,240,000 | 1.34% |
| Merlin Capital, Inc | 12,174 | $630,000 | 1.26% |
| Atlas Venture Associates IX, LLC | 10,000 | $518,000 | 1.18% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 111,440 | $5,768,000 | 1.16% |